Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Advanced Medical Solutions receives US regulatory approvals for two wound care products

The innovative dressings help prevent and treat infection and accelerate the healing
Advanced Medical Solutions receives US regulatory approvals for two wound care products
The products are for post-operative use

Wound care specialist Advanced Medical Solutions Group PLC (LON:AMS) has received the green light from the US regulator for two new products.

The Food & Drug Administration granted premarket 510(k) approvals for the group's post-operative dressing and foam dressing.

"These most recent approvals strengthen our advanced wound care portfolio in the US and provide further significant products to support our OEM customers and end users,” said chief executive Chris Meredith.

“We are particularly pleased to be able to demonstrate the value of our R&D and regulatory capabilities which are a key pillar of our strategy to drive organic growth."

View full AMS profile View Profile

Advanced Medical Solutions Group Timeline

Related Articles

scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
1528305384_Untitled-design-(3).jpg
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use